{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:21:20Z","timestamp":1790788880471,"version":"4.1.0"},"reference-count":175,"publisher":"Aging and Disease","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging and disease"],"published-print":{"date-parts":[[2023]]},"DOI":"10.14336\/ad.2023.0314","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T09:29:21Z","timestamp":1679477361000},"page":"2071","source":"Crossref","is-referenced-by-count":25,"title":["COVID-19 and Cardiovascular Diseases: From Cellular Mechanisms to Clinical Manifestations"],"prefix":"10.14336","volume":"14","author":[{"given":"Hongyang","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bala Musa","family":"Ceesay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhong","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao Wen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5462","reference":[{"key":"key-10.14336\/AD.2023.0314-1","doi-asserted-by":"crossref","unstructured":"To KK, Sridhar S, Chiu KH, Hung DL, Li X, Hung IF et al (2021). Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg Microbes Infect, 10:507-535.","DOI":"10.1080\/22221751.2021.1898291"},{"key":"key-10.14336\/AD.2023.0314-2","doi-asserted-by":"crossref","unstructured":"Harrison AG, Lin T, Wang P (2020). Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends Immunol, 41:1100-1115.","DOI":"10.1016\/j.it.2020.10.004"},{"key":"key-10.14336\/AD.2023.0314-3","doi-asserted-by":"crossref","unstructured":"Oran DP, Topol EJ (2021). The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review. Ann Intern Med, 174:655-662.","DOI":"10.7326\/M20-6976"},{"key":"key-10.14336\/AD.2023.0314-4","doi-asserted-by":"crossref","unstructured":"Guo M, Tao W, Flavell RA, Zhu S (2021). Potential intestinal infection and faecal-oral transmission of SARS-CoV-2. Nat Rev Gastroenterol Hepatol, 18:269-283.","DOI":"10.1038\/s41575-021-00416-6"},{"key":"key-10.14336\/AD.2023.0314-5","unstructured":"Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Lee SS (2020). SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Eur Rev Med Pharmacol Sci, 24:4016-4026."},{"key":"key-10.14336\/AD.2023.0314-6","doi-asserted-by":"crossref","unstructured":"Tomasoni D, Italia L, Adamo M, Inciardi RM, Lombardi CM, Solomon SD et al (2020). COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail, 22:957-966.","DOI":"10.1002\/ejhf.1871"},{"key":"key-10.14336\/AD.2023.0314-7","doi-asserted-by":"crossref","unstructured":"Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A et al (2020). Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail, 22:911-915.","DOI":"10.1002\/ejhf.1828"},{"key":"key-10.14336\/AD.2023.0314-8","doi-asserted-by":"crossref","unstructured":"Fried JA, Ramasubbu K, Bhatt R, Topkara VK, Clerkin KJ, Horn E et al (2020). The Variety of Cardiovascular Presentations of COVID-19. Circulation, 141:1930-1936.","DOI":"10.1161\/CIRCULATIONAHA.120.047164"},{"key":"key-10.14336\/AD.2023.0314-9","doi-asserted-by":"crossref","unstructured":"Hirschtick JL, Titus AR, Slocum E, Power LE, Hirschtick RE, Elliott MR et al (2021). Population-Based Estimates of Post-acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (PASC) Prevalence and Characteristics. Clin Infect Dis, 73:2055-2064.","DOI":"10.1093\/cid\/ciab408"},{"key":"key-10.14336\/AD.2023.0314-10","doi-asserted-by":"crossref","unstructured":"de Wit E, van Doremalen N, Falzarano D, Munster VJ (2016). SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol, 14:523-534.","DOI":"10.1038\/nrmicro.2016.81"},{"key":"key-10.14336\/AD.2023.0314-11","doi-asserted-by":"crossref","unstructured":"Bermingham A, Chand MA, Brown CS, Aarons E, Tong C, Langrish C et al (2012). Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill, 17:20290.","DOI":"10.2807\/ese.17.40.20290-en"},{"key":"key-10.14336\/AD.2023.0314-12","doi-asserted-by":"crossref","unstructured":"Alhogbani T (2016). Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. Ann Saudi Med, 36:78-80.","DOI":"10.5144\/0256-4947.2016.78"},{"key":"key-10.14336\/AD.2023.0314-13","doi-asserted-by":"crossref","unstructured":"Wu Y, Ho W, Huang Y, Jin DY, Li S, Liu SL et al (2020). SARS-CoV-2 is an appropriate name for the new coronavirus. Lancet, 395:949-950.","DOI":"10.1016\/S0140-6736(20)30557-2"},{"key":"key-10.14336\/AD.2023.0314-14","doi-asserted-by":"crossref","unstructured":"Sorci G, Faivre B, Morand S (2020). Explaining among-country variation in COVID-19 case fatality rate. Sci Rep, 10:18909.","DOI":"10.1038\/s41598-020-75848-2"},{"key":"key-10.14336\/AD.2023.0314-15","doi-asserted-by":"crossref","unstructured":"Sandoval Y, Januzzi JLJr., Jaffe AS (2020). Cardiac Troponin for Assessment of Myocardial Injury in COVID-19: JACC Review Topic of the Week. J Am Coll Cardiol, 76:1244-1258.","DOI":"10.1016\/j.jacc.2020.06.068"},{"key":"key-10.14336\/AD.2023.0314-16","unstructured":"Giustino G, Croft LB, Stefanini GG, Bragato R, Silbiger JJ, Vicenzi M et al (2020). Characterization of Myocardial Injury in Patients With COVID-19. J Am Coll Cardiol, 76:2043-2055."},{"key":"key-10.14336\/AD.2023.0314-17","doi-asserted-by":"crossref","unstructured":"Guo T, Fan YZ, Chen M, Wu XY, Zhang L, He T et al (2020). Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). Jama Cardiology, 5:811-818.","DOI":"10.1001\/jamacardio.2020.1017"},{"key":"key-10.14336\/AD.2023.0314-18","doi-asserted-by":"crossref","unstructured":"Zhou F, Yu T, Du RH, Fan GH, Liu Y, Liu ZB et al (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 395:1054-1062.","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"key-10.14336\/AD.2023.0314-19","doi-asserted-by":"crossref","unstructured":"Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F et al (2020). Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol, 5:802-810.","DOI":"10.1001\/jamacardio.2020.0950"},{"key":"key-10.14336\/AD.2023.0314-20","doi-asserted-by":"crossref","unstructured":"Lombardi CM, Carubelli V, Iorio A, Inciardi RM, Bellasi A, Canale C et al (2020). Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019: Results of a Multicenter Study. JAMA Cardiol, 5:1274-1280.","DOI":"10.1001\/jamacardio.2020.3538"},{"key":"key-10.14336\/AD.2023.0314-21","doi-asserted-by":"crossref","unstructured":"Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM et al (2020). Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J, 55.","DOI":"10.1183\/13993003.01227-2020"},{"key":"key-10.14336\/AD.2023.0314-22","doi-asserted-by":"crossref","unstructured":"Zaman S, MacIsaac AI, Jennings GL, Schlaich MP, Inglis SC, Arnold R et al (2020). Cardiovascular disease and COVID-19: Australian and New Zealand consensus statement. Med J Aust, 213:182-187.","DOI":"10.5694\/mja2.50714"},{"key":"key-10.14336\/AD.2023.0314-23","doi-asserted-by":"crossref","unstructured":"Garg P, Morris P, Fazlanie AL, Vijayan S, Dancso B, Dastidar AG et al (2017). Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin. Intern Emerg Med, 12:147-155.","DOI":"10.1007\/s11739-017-1612-1"},{"key":"key-10.14336\/AD.2023.0314-24","doi-asserted-by":"crossref","unstructured":"Dou Q, Wei X, Zhou K, Yang S, Jia P (2020). Cardiovascular Manifestations and Mechanisms in Patients with COVID-19. Trends Endocrinol Metab, 31:893-904.","DOI":"10.1016\/j.tem.2020.10.001"},{"key":"key-10.14336\/AD.2023.0314-25","doi-asserted-by":"crossref","unstructured":"Tanbo\u011fa IH, Canpolat U, \u00d6zcan \u00c7etin EH, Kundi H, Turan S, Celik O et al (2021). The prognostic role of cardiac troponin in hospitalized COVID-19 patients. Atherosclerosis, 325:83-88.","DOI":"10.1016\/j.atherosclerosis.2021.04.006"},{"key":"key-10.14336\/AD.2023.0314-26","doi-asserted-by":"crossref","unstructured":"Tajbakhsh A, Gheibi Hayat SM, Taghizadeh H, Akbari A, Inabadi M, Savardashtaki A et al (2021). COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther, 19:345-357.","DOI":"10.1080\/14787210.2020.1822737"},{"key":"key-10.14336\/AD.2023.0314-27","doi-asserted-by":"crossref","unstructured":"Garc\u00eda de Guadiana-Romualdo L, Morell-Garc\u00eda D, Rodr\u00edguez-Fraga O, Morales-Indiano C, Mar\u00eda Lourdes Padilla Jim\u00e9nez A, Guti\u00e9rrez Revilla JI et al (2021). Cardiac troponin and COVID-19 severity: Results from BIOCOVID study. Eur J Clin Invest, 51:e13532.","DOI":"10.1111\/eci.13532"},{"key":"key-10.14336\/AD.2023.0314-28","doi-asserted-by":"crossref","unstructured":"Inciardi RM, Adamo M, Lupi L, Cani DS, Di Pasquale M, Tomasoni D et al (2020). Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J, 41:1821-1829.","DOI":"10.1093\/eurheartj\/ehaa388"},{"key":"key-10.14336\/AD.2023.0314-29","doi-asserted-by":"crossref","unstructured":"Gaze DC (2020). Clinical utility of cardiac troponin measurement in COVID-19 infection. Ann Clin Biochem, 57:202-205.","DOI":"10.1177\/0004563220921888"},{"key":"key-10.14336\/AD.2023.0314-30","doi-asserted-by":"crossref","unstructured":"Metkus TS, Sokoll LJ, Barth AS, Czarny MJ, Hays AG, Lowenstein CJ et al (2021). Myocardial Injury in Severe COVID-19 Compared With Non-COVID-19 Acute Respiratory Distress Syndrome. Circulation, 143:553-565.","DOI":"10.1161\/CIRCULATIONAHA.120.050543"},{"key":"key-10.14336\/AD.2023.0314-31","doi-asserted-by":"crossref","unstructured":"Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G et al (2021). Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J, 42:1866-1878.","DOI":"10.1093\/eurheartj\/ehab075"},{"key":"key-10.14336\/AD.2023.0314-32","doi-asserted-by":"crossref","unstructured":"Liao SC, Shao SC, Cheng CW, Chen YC, Hung MJ (2020). Incidence rate and clinical impacts of arrhythmia following COVID-19: a systematic review and meta-analysis of 17,435 patients. Crit Care, 24:690.","DOI":"10.1186\/s13054-020-03368-6"},{"key":"key-10.14336\/AD.2023.0314-33","doi-asserted-by":"crossref","unstructured":"Turagam MK, Musikantow D, Goldman ME, Bassily-Marcus A, Chu E, Shivamurthy P et al (2020). Malignant Arrhythmias in Patients With COVID-19: Incidence, Mechanisms, and Outcomes. Circ Arrhythm Electrophysiol, 13:e008920.","DOI":"10.1161\/CIRCEP.120.008920"},{"key":"key-10.14336\/AD.2023.0314-34","doi-asserted-by":"crossref","unstructured":"Honore PM, Redant S, Preseau T, Moorthamers S, Kaefer K, Barreto Gutierrez L et al (2021). Higher incidence of arrhythmia in COVID-19 than in other community-acquired pneumonia: possible role of concurrent therapies. Crit Care, 25:259.","DOI":"10.1186\/s13054-021-03655-w"},{"key":"key-10.14336\/AD.2023.0314-35","doi-asserted-by":"crossref","unstructured":"Manolis AS, Manolis AA, Manolis TA, Apostolopoulos EJ, Papatheou D, Melita H (2020). COVID-19 infection and cardiac arrhythmias. Trends Cardiovasc Med, 30:451-460.","DOI":"10.1016\/j.tcm.2020.08.002"},{"key":"key-10.14336\/AD.2023.0314-36","doi-asserted-by":"crossref","unstructured":"Sapp JL, Alqarawi W, MacIntyre CJ, Tadros R, Steinberg C, Roberts JD et al (2020). Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. Can J Cardiol, 36:948-951.","DOI":"10.1016\/j.cjca.2020.04.003"},{"key":"key-10.14336\/AD.2023.0314-37","doi-asserted-by":"crossref","unstructured":"Huang C, Huang L, Wang Y, Li X, Ren L, Gu X et al (2021). 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet, 397:220-232.","DOI":"10.1016\/S0140-6736(20)32656-8"},{"key":"key-10.14336\/AD.2023.0314-38","doi-asserted-by":"crossref","unstructured":"St\u00e5hlberg M, Reistam U, Fedorowski A, Villacorta H, Horiuchi Y, Bax J et al (2021). Post-COVID-19 Tachycardia Syndrome: A Distinct Phenotype of Post-Acute COVID-19 Syndrome. Am J Med, 134:1451-1456.","DOI":"10.1016\/j.amjmed.2021.07.004"},{"key":"key-10.14336\/AD.2023.0314-39","doi-asserted-by":"crossref","unstructured":"Ren X, Wen W, Fan X, Hou W, Su B, Cai P et al (2021). COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell, 184:5838.","DOI":"10.1016\/j.cell.2021.10.023"},{"key":"key-10.14336\/AD.2023.0314-40","doi-asserted-by":"crossref","unstructured":"Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS et al (2020). Extrapulmonary manifestations of COVID-19. Nat Med, 26:1017-1032.","DOI":"10.1038\/s41591-020-0968-3"},{"key":"key-10.14336\/AD.2023.0314-41","doi-asserted-by":"crossref","unstructured":"van der Linden J, Almskog L, Liliequist A, Grip J, Fux T, Rysz S et al (2020). Thromboembolism, Hypercoagulopathy, and Antiphospholipid Antibodies in Critically Ill Coronavirus Disease 2019 Patients: A Before and After Study of Enhanced Anticoagulation. Crit Care Explor, 2:e0308.","DOI":"10.1097\/CCE.0000000000000308"},{"key":"key-10.14336\/AD.2023.0314-42","doi-asserted-by":"crossref","unstructured":"Li Y, Liu T, Tse G, Wu M, Jiang J, Liu M et al (2020). Electrocardiograhic characteristics in patients with coronavirus infection: A single-center observational study. Ann Noninvasive Electrocardiol, 25:e12805.","DOI":"10.1111\/anec.12805"},{"key":"key-10.14336\/AD.2023.0314-43","doi-asserted-by":"crossref","unstructured":"Katsoularis I, Fonseca-Rodr\u00edguez O, Farrington P, Lindmark K, Fors Connolly AM (2021). Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet, 398:599-607.","DOI":"10.1016\/S0140-6736(21)00896-5"},{"key":"key-10.14336\/AD.2023.0314-44","doi-asserted-by":"crossref","unstructured":"Hamadeh A, Aldujeli A, Briedis K, Tecson KM, Sanz-S\u00e1nchez J, Al Dujeili M et al (2020). Characteristics and Outcomes in Patients Presenting With COVID-19 and ST-Segment Elevation Myocardial Infarction. Am J Cardiol, 131:1-6.","DOI":"10.1016\/j.amjcard.2020.06.063"},{"key":"key-10.14336\/AD.2023.0314-45","doi-asserted-by":"crossref","unstructured":"Stefanini GG, Montorfano M, Trabattoni D, Andreini D, Ferrante G, Ancona M et al (2020). ST-Elevation Myocardial Infarction in Patients With COVID-19: Clinical and Angiographic Outcomes. Circulation, 141:2113-2116.","DOI":"10.1161\/CIRCULATIONAHA.120.047525"},{"key":"key-10.14336\/AD.2023.0314-46","doi-asserted-by":"crossref","unstructured":"Tsch\u00f6pe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB et al (2021). Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol, 18:169-193.","DOI":"10.1038\/s41569-020-00435-x"},{"key":"key-10.14336\/AD.2023.0314-47","unstructured":"Rezkalla SH, Kloner RA (2010). Influenza-related viral myocarditis. Wmj, 109:209-213."},{"key":"key-10.14336\/AD.2023.0314-48","doi-asserted-by":"crossref","unstructured":"Rezkalla SH, Kloner RA (2021). Viral myocarditis: 1917-2020: From the Influenza A to the COVID-19 pandemics. Trends Cardiovasc Med, 31:163-169.","DOI":"10.1016\/j.tcm.2020.12.007"},{"key":"key-10.14336\/AD.2023.0314-49","doi-asserted-by":"crossref","unstructured":"Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G, Winterton D (2020). Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms. J Card Fail, 26:470-475.","DOI":"10.1016\/j.cardfail.2020.04.009"},{"key":"key-10.14336\/AD.2023.0314-50","doi-asserted-by":"crossref","unstructured":"Ammirati E, Lupi L, Palazzini M, Hendren NS, Grodin JL, Cannistraci CV et al (2022). Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis. Circulation, 145:1123-1139.","DOI":"10.1161\/CIRCULATIONAHA.121.056817"},{"key":"key-10.14336\/AD.2023.0314-51","doi-asserted-by":"crossref","unstructured":"Halushka MK, Vander Heide RS (2021). Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. Cardiovasc Pathol, 50:107300.","DOI":"10.1016\/j.carpath.2020.107300"},{"key":"key-10.14336\/AD.2023.0314-52","doi-asserted-by":"crossref","unstructured":"Pollack A, Kontorovich AR, Fuster V, Dec GW (2015). Viral myocarditis--diagnosis, treatment options, and current controversies. Nat Rev Cardiol, 12:670-680.","DOI":"10.1038\/nrcardio.2015.108"},{"key":"key-10.14336\/AD.2023.0314-53","doi-asserted-by":"crossref","unstructured":"T\u00fcnnemann-Tarr A, St\u00f6be S, Laufs U, Hagendorff A, Tayal B (2020). Speckle tracking echocardiography in a patient with viral myocarditis and acute myocardial infarction. J Cardiol Cases, 22:184-191.","DOI":"10.1016\/j.jccase.2020.06.011"},{"key":"key-10.14336\/AD.2023.0314-54","doi-asserted-by":"crossref","unstructured":"Weckbach LT, Curta A, Bieber S, Kraechan A, Brado J, Hellmuth JC et al (2021). Myocardial Inflammation and Dysfunction in COVID-19-Associated Myocardial Injury. Circ Cardiovasc Imaging, 14:e012220.","DOI":"10.1161\/CIRCIMAGING.120.011713"},{"key":"key-10.14336\/AD.2023.0314-55","doi-asserted-by":"crossref","unstructured":"Kawakami R, Sakamoto A, Kawai K, Gianatti A, Pellegrini D, Nasr A et al (2021). Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week. J Am Coll Cardiol, 77:314-325.","DOI":"10.1016\/j.jacc.2020.11.031"},{"key":"key-10.14336\/AD.2023.0314-56","doi-asserted-by":"crossref","unstructured":"Bearse M, Hung YP, Krauson AJ, Bonanno L, Boyraz B, Harris CK et al (2021). Factors associated with myocardial SARS-CoV-2 infection, myocarditis, and cardiac inflammation in patients with COVID-19. Mod Pathol, 34:1345-1357.","DOI":"10.1038\/s41379-021-00790-1"},{"key":"key-10.14336\/AD.2023.0314-57","doi-asserted-by":"crossref","unstructured":"Lindner D, Fitzek A, Br\u00e4uninger H, Aleshcheva G, Edler C, Meissner K et al (2020). Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. JAMA Cardiol, 5:1281-1285.","DOI":"10.1001\/jamacardio.2020.3551"},{"key":"key-10.14336\/AD.2023.0314-58","doi-asserted-by":"crossref","unstructured":"Iacobellis G, Malavazos AE, Corsi MM (2011). Epicardial fat: from the biomolecular aspects to the clinical practice. Int J Biochem Cell Biol, 43:1651-1654.","DOI":"10.1016\/j.biocel.2011.09.006"},{"key":"key-10.14336\/AD.2023.0314-59","doi-asserted-by":"crossref","unstructured":"Malavazos AE, Goldberger JJ, Iacobellis G (2020). Does epicardial fat contribute to COVID-19 myocardial inflammation? Eur Heart J, 41:2333.","DOI":"10.1093\/eurheartj\/ehaa471"},{"key":"key-10.14336\/AD.2023.0314-60","doi-asserted-by":"crossref","unstructured":"Boorsma EM, Ter Maaten JM, Damman K, Dinh W, Gustafsson F, Goldsmith S et al (2020). Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol, 17:641-655.","DOI":"10.1038\/s41569-020-0379-7"},{"key":"key-10.14336\/AD.2023.0314-61","doi-asserted-by":"crossref","unstructured":"Caro-Cod\u00f3n J, Rey JR, Bu\u00f1o A, Iniesta AM, Rosillo SO, Castrejon-Castrejon S et al (2021). Characterization of NT-proBNP in a large cohort of COVID-19 patients. Eur J Heart Fail, 23:456-464.","DOI":"10.1002\/ejhf.2095"},{"key":"key-10.14336\/AD.2023.0314-62","doi-asserted-by":"crossref","unstructured":"Tomasoni D, Inciardi RM, Lombardi CM, Tedino C, Agostoni P, Ameri P et al (2020). Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study. Eur J Heart Fail, 22:2238-2247.","DOI":"10.1002\/ejhf.2052"},{"key":"key-10.14336\/AD.2023.0314-63","unstructured":"CAPACITY-COVID Collaborative Consortium and LEOSS Study Group (2022). Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries. Eur Heart J, 43:1104-1120."},{"key":"key-10.14336\/AD.2023.0314-64","doi-asserted-by":"crossref","unstructured":"Salzano A, D'Assante R, Stagnaro FM, Valente V, Crisci G, Giardino F et al (2020). Heart failure management during the COVID-19 outbreak in Italy: a telemedicine experience from a heart failure university tertiary referral centre. Eur J Heart Fail, 22:1048-1050.","DOI":"10.1002\/ejhf.1911"},{"key":"key-10.14336\/AD.2023.0314-65","doi-asserted-by":"crossref","unstructured":"K\u00f6nig S, Hohenstein S, Meier-Hellmann A, Kuhlen R, Hindricks G, Bollmann A (2020). In-hospital care in acute heart failure during the COVID-19 pandemic: insights from the German-wide Helios hospital network. Eur J Heart Fail, 22:2190-2201.","DOI":"10.1002\/ejhf.2044"},{"key":"key-10.14336\/AD.2023.0314-66","doi-asserted-by":"crossref","unstructured":"Bromage DI, Cannat\u00e0 A, Rind IA, Gregorio C, Piper S, Shah AM et al (2020). The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic. Eur J Heart Fail, 22:978-984.","DOI":"10.1002\/ejhf.1925"},{"key":"key-10.14336\/AD.2023.0314-67","doi-asserted-by":"crossref","unstructured":"Varshney AS, Omar WA, Goodrich EL, Bhatt AS, Wolley AE, Gong J et al (2021). Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. Circ Heart Fail, 14:e008477.","DOI":"10.1161\/CIRCHEARTFAILURE.121.008477"},{"key":"key-10.14336\/AD.2023.0314-68","doi-asserted-by":"crossref","unstructured":"Albert CL, Carmona-Rubio AE, Weiss AJ, Procop GG, Starling RC, Rodriguez ER (2020). The Enemy Within: Sudden-Onset Reversible Cardiogenic Shock With Biopsy-Proven Cardiac Myocyte Infection by Severe Acute Respiratory Syndrome Coronavirus 2. Circulation, 142:1865-1870.","DOI":"10.1161\/CIRCULATIONAHA.120.050097"},{"key":"key-10.14336\/AD.2023.0314-69","doi-asserted-by":"crossref","unstructured":"Bonnet M, Champagnac A, Lantelme P, Harbaoui B (2020). Endomyocardial biopsy findings in Kawasaki-like disease associated with SARS-CoV-2. Eur Heart J, 41:3863-3864.","DOI":"10.1093\/eurheartj\/ehaa588"},{"key":"key-10.14336\/AD.2023.0314-70","doi-asserted-by":"crossref","unstructured":"Alsaied T, Tremoulet AH, Burns JC, Saidi A, Dionne A, Lang SM et al (2021). Review of Cardiac Involvement in Multisystem Inflammatory Syndrome in Children. Circulation, 143:78-88.","DOI":"10.1161\/CIRCULATIONAHA.120.049836"},{"key":"key-10.14336\/AD.2023.0314-71","doi-asserted-by":"crossref","unstructured":"Chau VQ, Giustino G, Mahmood K, Oliveros E, Neibart E, Oloomi M et al (2020). Cardiogenic Shock and Hyperinflammatory Syndrome in Young Males With COVID-19. Circ Heart Fail, 13:e007485.","DOI":"10.1161\/CIRCHEARTFAILURE.120.007485"},{"key":"key-10.14336\/AD.2023.0314-72","doi-asserted-by":"crossref","unstructured":"Methvin L, Liu SD, Dodge SE, Gilstrap LG (2022). Opposing forces of cardiogenic shock: left ventricular outflow obstruction, severe mitral regurgitation, and left ventricular dysfunction in Takotsubo cardiomyopathy. ESC Heart Fail. 9:2719-2723","DOI":"10.1002\/ehf2.13936"},{"key":"key-10.14336\/AD.2023.0314-73","doi-asserted-by":"crossref","unstructured":"Zhai Z, Li C, Chen Y, Gerotziafas G, Zhang Z, Wan J et al (2020). Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. Thromb Haemost, 120:937-948.","DOI":"10.1055\/s-0040-1710019"},{"key":"key-10.14336\/AD.2023.0314-74","doi-asserted-by":"crossref","unstructured":"Tan BK, Mainbourg S, Friggeri A, Bertoletti L, Douplat M, Dargaud Y et al (2021). Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax, 76:970-979.","DOI":"10.1136\/thoraxjnl-2020-215383"},{"key":"key-10.14336\/AD.2023.0314-75","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez D, Garc\u00eda-Sanchez A, Rali P, Muriel A, Bikdeli B, Ruiz-Artacho P et al (2021). Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Chest, 159:1182-1196.","DOI":"10.1016\/j.chest.2020.11.005"},{"key":"key-10.14336\/AD.2023.0314-76","doi-asserted-by":"crossref","unstructured":"Wichmann D, Sperhake JP, L\u00fctgehetmann M, Steurer S, Edler C, Heinemann A et al (2020). Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med, 173:268-277.","DOI":"10.7326\/M20-2003"},{"key":"key-10.14336\/AD.2023.0314-77","doi-asserted-by":"crossref","unstructured":"Wu T, Zuo Z, Yang D, Luo X, Jiang L, Xia Z et al (2021). Venous thromboembolic events in patients with COVID-19: a systematic review and meta-analysis. Age Ageing, 50:284-293.","DOI":"10.1093\/ageing\/afaa259"},{"key":"key-10.14336\/AD.2023.0314-78","doi-asserted-by":"crossref","unstructured":"Stefely JA, Christensen BB, Gogakos T, Cone Sullivan JK, Montgomery GG, Barranco JP et al (2020). Marked factor V activity elevation in severe COVID-19 is associated with venous thromboembolism. Am J Hematol, 95:1522-1530.","DOI":"10.1002\/ajh.25979"},{"key":"key-10.14336\/AD.2023.0314-79","doi-asserted-by":"crossref","unstructured":"Chi G, Lee JJ, Jamil A, Gunnam V, Najafi H, Memar Montazerin S et al (2020). Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis. J Clin Med, 9.","DOI":"10.3390\/jcm9082489"},{"key":"key-10.14336\/AD.2023.0314-80","doi-asserted-by":"crossref","unstructured":"Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P et al (2020). Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol, 7:e575-e582.","DOI":"10.1016\/S2352-3026(20)30216-7"},{"key":"key-10.14336\/AD.2023.0314-81","doi-asserted-by":"crossref","unstructured":"de Montmollin E, Faille D, Andrieu V, Ajzenberg N, Timsit JF (2021). Intensified thromboprophylaxis in COVID-19 critically ill patients: Is it enough? J Infect, 82:e20-e22.","DOI":"10.1016\/j.jinf.2021.02.003"},{"key":"key-10.14336\/AD.2023.0314-82","doi-asserted-by":"crossref","unstructured":"Flumignan RL, Civile VT, Tin\u00f4co JDS, Pascoal PI, Areias LL, Matar CF et al (2022). Anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev, 3:Cd013739.","DOI":"10.1002\/14651858.CD013739.pub2"},{"key":"key-10.14336\/AD.2023.0314-83","doi-asserted-by":"crossref","unstructured":"Nicin L, Abplanalp WT, Mellentin H, Kattih B, Tombor L, John D et al (2020). Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. Eur Heart J, 41:1804-1806.","DOI":"10.1093\/eurheartj\/ehaa311"},{"key":"key-10.14336\/AD.2023.0314-84","doi-asserted-by":"crossref","unstructured":"Hikmet F, M\u00e9ar L, Edvinsson \u00c5, Micke P, Uhl\u00e9n M, Lindskog C (2020). The protein expression profile of ACE2 in human tissues. Mol Syst Biol, 16:e9610.","DOI":"10.15252\/msb.20209610"},{"key":"key-10.14336\/AD.2023.0314-85","doi-asserted-by":"crossref","unstructured":"Bargehr J, Rericha P, Petchey A, Colzani M, Moule G, Malgapo MC et al (2021). Cardiovascular ACE2 receptor expression in patients undergoing heart transplantation. ESC Heart Fail, 8:4119-4129.","DOI":"10.1002\/ehf2.13528"},{"key":"key-10.14336\/AD.2023.0314-86","doi-asserted-by":"crossref","unstructured":"Vukusic K, Thorsell A, Muslimovic A, Jonsson M, Dellgren G, Lindahl A et al (2022). Overexpression of the SARS-CoV-2 receptor angiotensin converting enzyme 2 in cardiomyocytes of failing hearts. Sci Rep, 12:965.","DOI":"10.1038\/s41598-022-04956-y"},{"key":"key-10.14336\/AD.2023.0314-87","doi-asserted-by":"crossref","unstructured":"Liu H, Gai S, Wang X, Zeng J, Sun C, Zhao Y et al (2020). Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart. Cardiovasc Res, 116:1733-1741.","DOI":"10.1093\/cvr\/cvaa191"},{"key":"key-10.14336\/AD.2023.0314-88","doi-asserted-by":"crossref","unstructured":"Mills RJ, Humphrey SJ, Fortuna PRJ, Lor M, Foster SR, Quaife-Ryan GA et al (2021). BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. Cell, 184:2167-2182.e2122.","DOI":"10.1016\/j.cell.2021.03.026"},{"key":"key-10.14336\/AD.2023.0314-89","doi-asserted-by":"crossref","unstructured":"Samelson AJ, Tran QD, Robinot R, Carrau L, Rezelj VV, Mac Kain A et al (2021). BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2. bioRxiv.","DOI":"10.1101\/2021.01.19.427194"},{"key":"key-10.14336\/AD.2023.0314-90","doi-asserted-by":"crossref","unstructured":"Lu D, Chatterjee S, Xiao K, Riedel I, Wang Y, Foo R et al (2020). MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes. J Mol Cell Cardiol, 148:46-49.","DOI":"10.1016\/j.yjmcc.2020.08.017"},{"key":"key-10.14336\/AD.2023.0314-91","doi-asserted-by":"crossref","unstructured":"D'Onofrio N, Scisciola L, Sardu C, Trotta MC, De Feo M, Maiello C et al (2021). Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte. Cardiovasc Diabetol, 20:99.","DOI":"10.1186\/s12933-021-01286-7"},{"key":"key-10.14336\/AD.2023.0314-92","doi-asserted-by":"crossref","unstructured":"Bailey AL, Dmytrenko O, Greenberg L, Bredemeyer AL, Ma P, Liu J et al (2021). SARS-CoV-2 Infects Human Engineered Heart Tissues and Models COVID-19 Myocarditis. JACC Basic Transl Sci, 6:331-345.","DOI":"10.1016\/j.jacbts.2021.01.002"},{"key":"key-10.14336\/AD.2023.0314-93","doi-asserted-by":"crossref","unstructured":"Perez-Bermejo JA, Kang S, Rockwood SJ, Simoneau CR, Joy DA, Silva AC et al (2021). SARS-CoV-2 infection of human iPSC-derived cardiac cells reflects cytopathic features in hearts of patients with COVID-19. Sci Transl Med, 13.","DOI":"10.1126\/scitranslmed.abf7872"},{"key":"key-10.14336\/AD.2023.0314-94","doi-asserted-by":"crossref","unstructured":"Bojkova D, Wagner JUG, Shumliakivska M, Aslan GS, Saleem U, Hansen A et al (2020). SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. Cardiovasc Res, 116:2207-2215.","DOI":"10.1093\/cvr\/cvaa267"},{"key":"key-10.14336\/AD.2023.0314-95","doi-asserted-by":"crossref","unstructured":"Navaratnarajah CK, Pease DR, Halfmann PJ, Taye B, Barkhymer A, Howell KG et al (2021). Highly Efficient SARS-CoV-2 Infection of Human Cardiomyocytes: Spike Protein-Mediated Cell Fusion and Its Inhibition. J Virol, 95:e0136821.","DOI":"10.1128\/JVI.01368-21"},{"key":"key-10.14336\/AD.2023.0314-96","doi-asserted-by":"crossref","unstructured":"Wong CK, Luk HK, Lai WH, Lau YM, Zhang RR, Wong AC et al (2020). Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Platform to Study SARS-CoV-2 Related Myocardial Injury. Circ J, 84:2027-2031.","DOI":"10.1253\/circj.CJ-20-0881"},{"key":"key-10.14336\/AD.2023.0314-97","doi-asserted-by":"crossref","unstructured":"Bailey AL, Dmytrenko O, Greenberg L, Bredemeyer AL, Ma P, Liu J et al (2020). SARS-CoV-2 Infects Human Engineered Heart Tissues and Models COVID-19 Myocarditis. bioRxiv.","DOI":"10.1101\/2020.11.04.364315"},{"key":"key-10.14336\/AD.2023.0314-98","doi-asserted-by":"crossref","unstructured":"Marchiano S, Hsiang TY, Khanna A, Higashi T, Whitmore LS, Bargehr J et al (2021). SARS-CoV-2 Infects Human Pluripotent Stem Cell-Derived Cardiomyocytes, Impairing Electrical and Mechanical Function. Stem Cell Reports, 16:478-492.","DOI":"10.1016\/j.stemcr.2021.02.008"},{"key":"key-10.14336\/AD.2023.0314-99","doi-asserted-by":"crossref","unstructured":"Sharma A, Garcia GJr., Wang Y, Plummer JT, Morizono K, Arumugaswami V et al (2020). Human iPSC-Derived Cardiomyocytes Are Susceptible to SARS-CoV-2 Infection. Cell Rep Med, 1:100052.","DOI":"10.1016\/j.xcrm.2020.100052"},{"key":"key-10.14336\/AD.2023.0314-100","doi-asserted-by":"crossref","unstructured":"Lee CY, Huang CH, Rastegari E, Rengganaten V, Liu PC, Tsai PH et al (2021). Tumor Necrosis Factor-Alpha Exacerbates Viral Entry in SARS-CoV2-Infected iPSC-Derived Cardiomyocytes. Int J Mol Sci, 22.","DOI":"10.3390\/ijms22189869"},{"key":"key-10.14336\/AD.2023.0314-101","doi-asserted-by":"crossref","unstructured":"Lee LL, Chintalgattu V (2019). Pericytes in the Heart. Adv Exp Med Biol, 1122:187-210.","DOI":"10.1007\/978-3-030-11093-2_11"},{"key":"key-10.14336\/AD.2023.0314-102","doi-asserted-by":"crossref","unstructured":"Murray IR, Baily JE, Chen WCW, Dar A, Gonzalez ZN, Jensen AR et al (2017). Skeletal and cardiac muscle pericytes: Functions and therapeutic potential. Pharmacol Ther, 171:65-74.","DOI":"10.1016\/j.pharmthera.2016.09.005"},{"key":"key-10.14336\/AD.2023.0314-103","doi-asserted-by":"crossref","unstructured":"Nees S, Weiss DR, Senftl A, Knott M, F\u00f6rch S, Schnurr M et al (2012). Isolation, bulk cultivation, and characterization of coronary microvascular pericytes: the second most frequent myocardial cell type in vitro. Am J Physiol Heart Circ Physiol, 302:H69-84.","DOI":"10.1152\/ajpheart.00359.2011"},{"key":"key-10.14336\/AD.2023.0314-104","doi-asserted-by":"crossref","unstructured":"Dalkara T, Gursoy-Ozdemir Y, Yemisci M (2011). Brain microvascular pericytes in health and disease. Acta Neuropathol, 122:1-9.","DOI":"10.1007\/s00401-011-0847-6"},{"key":"key-10.14336\/AD.2023.0314-105","doi-asserted-by":"crossref","unstructured":"Thomas WE (1999). Brain macrophages: on the role of pericytes and perivascular cells. Brain Res Brain Res Rev, 31:42-57.","DOI":"10.1016\/S0165-0173(99)00024-7"},{"key":"key-10.14336\/AD.2023.0314-106","doi-asserted-by":"crossref","unstructured":"Jones OY, Yeralan S (2022). Is Long COVID a State of Systemic Pericyte Disarray? J Clin Med, 11.","DOI":"10.3390\/jcm11030572"},{"key":"key-10.14336\/AD.2023.0314-107","doi-asserted-by":"crossref","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S et al (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181:271-280.e278.","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"key-10.14336\/AD.2023.0314-108","doi-asserted-by":"crossref","unstructured":"Maccio U, Zinkernagel AS, Shambat SM, Zeng X, Cathomas G, Ruschitzka F et al (2021). SARS-CoV-2 leads to a small vessel endotheliitis in the heart. EBioMedicine, 63:103182.","DOI":"10.1016\/j.ebiom.2020.103182"},{"key":"key-10.14336\/AD.2023.0314-109","doi-asserted-by":"crossref","unstructured":"Cardot-Leccia N, Hubiche T, Dellamonica J, Burel-Vandenbos F, Passeron T (2020). Pericyte alteration sheds light on micro-vasculopathy in COVID-19 infection. Intensive Care Med, 46:1777-1778.","DOI":"10.1007\/s00134-020-06147-7"},{"key":"key-10.14336\/AD.2023.0314-110","doi-asserted-by":"crossref","unstructured":"Monteil V, Kwon H, Prado P, Hagelkr\u00fcys A, Wimmer RA, Stahl M et al (2020). Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell, 181:905-913.e907.","DOI":"10.1016\/j.cell.2020.04.004"},{"key":"key-10.14336\/AD.2023.0314-111","doi-asserted-by":"crossref","unstructured":"Avolio E, Carrabba M, Milligan R, Kavanagh Williamson M, Beltrami AP, Gupta K et al (2021). The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease. Clin Sci (Lond), 135:2667-2689.","DOI":"10.1042\/CS20210735"},{"key":"key-10.14336\/AD.2023.0314-112","doi-asserted-by":"crossref","unstructured":"Siddiqi HK, Libby P, Ridker PM (2021). COVID-19 - A vascular disease. Trends Cardiovasc Med, 31:1-5.","DOI":"10.1016\/j.tcm.2020.10.005"},{"key":"key-10.14336\/AD.2023.0314-113","doi-asserted-by":"crossref","unstructured":"Nascimento Conde J, Schutt WR, Gorbunova EE, Mackow ER (2020). Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses. mBio, 11.","DOI":"10.1128\/mBio.03185-20"},{"key":"key-10.14336\/AD.2023.0314-114","doi-asserted-by":"crossref","unstructured":"Schimmel L, Chew KY, Stocks CJ, Yordanov TE, Essebier P, Kulasinghe A et al (2021). Endothelial cells are not productively infected by SARS-CoV-2. Clin Transl Immunology, 10:e1350.","DOI":"10.1002\/cti2.1350"},{"key":"key-10.14336\/AD.2023.0314-115","doi-asserted-by":"crossref","unstructured":"McCracken IR, Saginc G, He L, Huseynov A, Daniels A, Fletcher S et al (2021). Lack of Evidence of Angiotensin-Converting Enzyme 2 Expression and Replicative Infection by SARS-CoV-2 in Human Endothelial Cells. Circulation, 143:865-868.","DOI":"10.1161\/CIRCULATIONAHA.120.052824"},{"key":"key-10.14336\/AD.2023.0314-116","doi-asserted-by":"crossref","unstructured":"Nicosia RF, Ligresti G, Caporarello N, Akilesh S, Ribatti D (2021). COVID-19 Vasculopathy: Mounting Evidence for an Indirect Mechanism of Endothelial Injury. Am J Pathol, 191:1374-1384.","DOI":"10.1016\/j.ajpath.2021.05.007"},{"key":"key-10.14336\/AD.2023.0314-117","doi-asserted-by":"crossref","unstructured":"Syed F, Li W, Relich RF, Russell PM, Zhang S, Zimmerman MK et al (2021). Excessive Matrix Metalloproteinase-1 and Hyperactivation of Endothelial Cells Occurred in COVID-19 Patients and Were Associated With the Severity of COVID-19. J Infect Dis, 224:60-69.","DOI":"10.1093\/infdis\/jiab167"},{"key":"key-10.14336\/AD.2023.0314-118","doi-asserted-by":"crossref","unstructured":"Guervilly C, Burtey S, Sabatier F, Cauchois R, Lano G, Abdili E et al (2020). Circulating Endothelial Cells as a Marker of Endothelial Injury in Severe COVID -19. J Infect Dis, 222:1789-1793.","DOI":"10.1093\/infdis\/jiaa528"},{"key":"key-10.14336\/AD.2023.0314-119","doi-asserted-by":"crossref","unstructured":"Pons S, Fodil S, Azoulay E, Zafrani L (2020). The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care, 24:353.","DOI":"10.1186\/s13054-020-03062-7"},{"key":"key-10.14336\/AD.2023.0314-120","doi-asserted-by":"crossref","unstructured":"Rauch A, Dupont A, Goutay J, Caplan M, Staessens S, Moussa M et al (2020). Endotheliopathy Is Induced by Plasma From Critically Ill Patients and Associated With Organ Failure in Severe COVID-19. Circulation, 142:1881-1884.","DOI":"10.1161\/CIRCULATIONAHA.120.050907"},{"key":"key-10.14336\/AD.2023.0314-121","doi-asserted-by":"crossref","unstructured":"Lee S, Yu Y, Trimpert J, Benthani F, Mairhofer M, Richter-Pechanska P et al (2021). Virus-induced senescence is a driver and therapeutic target in COVID-19. Nature, 599:283-289.","DOI":"10.1038\/s41586-021-03995-1"},{"key":"key-10.14336\/AD.2023.0314-122","doi-asserted-by":"crossref","unstructured":"Kang S, Tanaka T, Inoue H, Ono C, Hashimoto S, Kioi Y et al (2020). IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proc Natl Acad Sci U S A, 117:22351-22356.","DOI":"10.1073\/pnas.2010229117"},{"key":"key-10.14336\/AD.2023.0314-123","doi-asserted-by":"crossref","unstructured":"Chen L, Li X, Chen M, Feng Y, Xiong C (2020). The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res, 116:1097-1100.","DOI":"10.1093\/cvr\/cvaa078"},{"key":"key-10.14336\/AD.2023.0314-124","doi-asserted-by":"crossref","unstructured":"Domizio JD, Gulen MF, Saidoune F, Thacker VV, Yatim A, Sharma K et al (2022). The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. Nature, 603:145-151.","DOI":"10.1038\/s41586-022-04421-w"},{"key":"key-10.14336\/AD.2023.0314-125","doi-asserted-by":"crossref","unstructured":"Tallquist MD, Molkentin JD (2017). Redefining the identity of cardiac fibroblasts. Nat Rev Cardiol, 14:484-491.","DOI":"10.1038\/nrcardio.2017.57"},{"key":"key-10.14336\/AD.2023.0314-126","doi-asserted-by":"crossref","unstructured":"Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC (2016). Cardiac Fibrosis: The Fibroblast Awakens. Circ Res, 118:1021-1040.","DOI":"10.1161\/CIRCRESAHA.115.306565"},{"key":"key-10.14336\/AD.2023.0314-127","doi-asserted-by":"crossref","unstructured":"Kong P, Christia P, Frangogiannis NG (2014). The pathogenesis of cardiac fibrosis. Cell Mol Life Sci, 71:549-574.","DOI":"10.1007\/s00018-013-1349-6"},{"key":"key-10.14336\/AD.2023.0314-128","doi-asserted-by":"crossref","unstructured":"Frangogiannis NG (2021). Cardiac fibrosis. Cardiovasc Res, 117:1450-1488.","DOI":"10.1093\/cvr\/cvaa324"},{"key":"key-10.14336\/AD.2023.0314-129","unstructured":"Delorey TM, Ziegler CGK, Heimberg G, Normand R, Yang Y, Segerstolpe \u00c5 et al (2021). COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature, 595:107-113."},{"key":"key-10.14336\/AD.2023.0314-130","doi-asserted-by":"crossref","unstructured":"Freda CT, Yin W, Ghebrehiwet B, Rubenstein DA (2021). SARS-CoV-2 proteins regulate inflammatory, thrombotic and diabetic responses in human arterial fibroblasts. Clin Immunol, 227:108733.","DOI":"10.1016\/j.clim.2021.108733"},{"key":"key-10.14336\/AD.2023.0314-131","doi-asserted-by":"crossref","unstructured":"Coomes EA, Haghbayan H (2020). Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev Med Virol, 30:1-9.","DOI":"10.1002\/rmv.2141"},{"key":"key-10.14336\/AD.2023.0314-132","doi-asserted-by":"crossref","unstructured":"Shafiabadi Hassani N, Talakoob H, Karim H, Mozafari Bazargany MH, Rastad H (2022). Cardiac Magnetic Resonance Imaging Findings in 2954 COVID-19 Adult Survivors: A Comprehensive Systematic Review. J Magn Reson Imaging, 55:866-880.","DOI":"10.1002\/jmri.27852"},{"key":"key-10.14336\/AD.2023.0314-133","doi-asserted-by":"crossref","unstructured":"Weber B, Siddiqi H, Zhou G, Vieira J, Kim A, Rutherford H et al (2022). Relationship Between Myocardial Injury During Index Hospitalization for SARS-CoV-2 Infection and Longer-Term Outcomes. J Am Heart Assoc, 11:e022010.","DOI":"10.1161\/JAHA.121.022010"},{"key":"key-10.14336\/AD.2023.0314-134","doi-asserted-by":"crossref","unstructured":"Clark DE, Dendy JM, Li DL, Crum K, Dixon D, George-Durrett K et al (2021). Cardiovascular magnetic resonance evaluation of soldiers after recovery from symptomatic SARS-CoV-2 infection: a case-control study of cardiovascular post-acute sequelae of SARS-CoV-2 infection (CV PASC). J Cardiovasc Magn Reson, 23:106.","DOI":"10.1186\/s12968-021-00798-1"},{"key":"key-10.14336\/AD.2023.0314-135","doi-asserted-by":"crossref","unstructured":"Chaturvedi H, Issac R, Sharma SK, Gupta R (2022). Progressive left and right heart dysfunction in coronavirus disease-19: Prospective echocardiographic evaluation. Eur Heart J Cardiovasc Imaging, 23:319-325.","DOI":"10.1093\/ehjci\/jeab268"},{"key":"key-10.14336\/AD.2023.0314-136","doi-asserted-by":"crossref","unstructured":"Joy G, Artico J, Kurdi H, Seraphim A, Lau C, Thornton GD et al (2021). Prospective Case-Control Study of Cardiovascular Abnormalities 6 Months Following Mild COVID-19 in Healthcare Workers. JACC Cardiovasc Imaging, 14:2155-2166.","DOI":"10.1016\/j.jcmg.2021.04.011"},{"key":"key-10.14336\/AD.2023.0314-137","doi-asserted-by":"crossref","unstructured":"Bartoszek M, Ma\u0142ek \u0141 A, Barczuk-Fal\u0119cka M, Brzewski M (2022). Cardiac Magnetic Resonance Follow-Up of Children After Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 With Initial Cardiac Involvement. J Magn Reson Imaging, 55:883-891.","DOI":"10.1002\/jmri.27870"},{"key":"key-10.14336\/AD.2023.0314-138","doi-asserted-by":"crossref","unstructured":"Vago H, Szabo L, Dohy Z, Merkely B (2021). Cardiac Magnetic Resonance Findings in Patients Recovered From COVID-19: Initial Experiences in Elite Athletes. JACC Cardiovasc Imaging, 14:1279-1281.","DOI":"10.1016\/j.jcmg.2020.11.014"},{"key":"key-10.14336\/AD.2023.0314-139","doi-asserted-by":"crossref","unstructured":"Cavigli L, Cillis M, Mochi V, Frascaro F, Mochi N, Hajdarevic A et al (2022). SARS-CoV-2 infection and return to play in junior competitive athletes: is systematic cardiac screening needed? Br J Sports Med, 56:264-270.","DOI":"10.1136\/bjsports-2021-104764"},{"key":"key-10.14336\/AD.2023.0314-140","doi-asserted-by":"crossref","unstructured":"Xie Y, Xu E, Bowe B, Al-Aly Z (2022). Long-term cardiovascular outcomes of COVID-19. Nat Med, 28:583-590.","DOI":"10.1038\/s41591-022-01689-3"},{"key":"key-10.14336\/AD.2023.0314-141","doi-asserted-by":"crossref","unstructured":"Singh T, Kite TA, Joshi SS, Spath NB, Kershaw L, Baker A et al (2022). MRI and CT coronary angiography in survivors of COVID-19. Heart, 108:46-53.","DOI":"10.1136\/heartjnl-2021-319926"},{"key":"key-10.14336\/AD.2023.0314-142","doi-asserted-by":"crossref","unstructured":"Maamar M, Artime A, Pariente E, Fierro P, Ruiz Y, Guti\u00e9rrez S et al (2022). Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: a cross-sectional study. Curr Med Res Opin, 38:901-909.","DOI":"10.1080\/03007995.2022.2042991"},{"key":"key-10.14336\/AD.2023.0314-143","doi-asserted-by":"crossref","unstructured":"Doykov I, H\u00e4llqvist J, Gilmour KC, Grandjean L, Mills K, Heywood WE (2020). 'The long tail of Covid-19' - The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Res, 9:1349.","DOI":"10.12688\/f1000research.27287.1"},{"key":"key-10.14336\/AD.2023.0314-144","doi-asserted-by":"crossref","unstructured":"Crook H, Raza S, Nowell J, Young M, Edison P (2021). Long covid-mechanisms, risk factors, and management. Bmj, 374:n1648.","DOI":"10.1136\/bmj.n1648"},{"key":"key-10.14336\/AD.2023.0314-145","doi-asserted-by":"crossref","unstructured":"Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK et al (2022). Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol, 23:210-216.","DOI":"10.1038\/s41590-021-01113-x"},{"key":"key-10.14336\/AD.2023.0314-146","doi-asserted-by":"crossref","unstructured":"Barrea L, Verde L, Grant WB, Frias-Toral E, Sarno G, Vetrani C et al (2022). Vitamin D: A Role Also in Long COVID-19? Nutrients, 14.","DOI":"10.3390\/nu14081625"},{"key":"key-10.14336\/AD.2023.0314-147","doi-asserted-by":"crossref","unstructured":"Vollbracht C, Kraft K (2022). Oxidative Stress and Hyper-Inflammation as Major Drivers of Severe COVID-19 and Long COVID: Implications for the Benefit of High-Dose Intravenous Vitamin C. Front Pharmacol, 13:899198.","DOI":"10.3389\/fphar.2022.899198"},{"key":"key-10.14336\/AD.2023.0314-148","doi-asserted-by":"crossref","unstructured":"Satoh T, Trudler D, Oh CK, Lipton SA (2022). Potential Therapeutic Use of the Rosemary Diterpene Carnosic Acid for Alzheimer's Disease, Parkinson's Disease, and Long-COVID through NRF2 Activation to Counteract the NLRP3 Inflammasome. Antioxidants (Basel), 11.","DOI":"10.3390\/antiox11010124"},{"key":"key-10.14336\/AD.2023.0314-149","doi-asserted-by":"crossref","unstructured":"Silva Andrade B, Siqueira S, de Assis Soares WR, de Souza Rangel F, Santos NO, Dos Santos Freitas A et al (2021). Long-COVID and Post-COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms. Viruses, 13.","DOI":"10.3390\/v13040700"},{"key":"key-10.14336\/AD.2023.0314-150","doi-asserted-by":"crossref","unstructured":"Ahamed J, Laurence J (2022). Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. J Clin Invest, 132.","DOI":"10.1172\/JCI161167"},{"key":"key-10.14336\/AD.2023.0314-151","doi-asserted-by":"crossref","unstructured":"Cooper SL, Boyle E, Jefferson SR, Heslop CRA, Mohan P, Mohanraj GGJ et al (2021). Role of the Renin-Angiotensin-Aldosterone and Kinin-Kallikrein Systems in the Cardiovascular Complications of COVID-19 and Long COVID. Int J Mol Sci, 22.","DOI":"10.3390\/ijms22158255"},{"key":"key-10.14336\/AD.2023.0314-152","doi-asserted-by":"crossref","unstructured":"Tatsis N, Ertl HC (2004). Adenoviruses as vaccine vectors. Mol Ther, 10:616-629.","DOI":"10.1016\/j.ymthe.2004.07.013"},{"key":"key-10.14336\/AD.2023.0314-153","doi-asserted-by":"crossref","unstructured":"Jain S, Venkataraman A, Wechsler ME, Peppas NA (2021). Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic. Adv Drug Deliv Rev, 179:114000.","DOI":"10.1016\/j.addr.2021.114000"},{"key":"key-10.14336\/AD.2023.0314-154","doi-asserted-by":"crossref","unstructured":"Luk A, Clarke B, Dahdah N, Ducharme A, Krahn A, McCrindle B et al (2021). Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers. Can J Cardiol, 37:1629-1634.","DOI":"10.1016\/j.cjca.2021.08.001"},{"key":"key-10.14336\/AD.2023.0314-155","doi-asserted-by":"crossref","unstructured":"Carli G, Nichele I, Ruggeri M, Barra S, Tosetto A (2021). Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine. Intern Emerg Med, 16:803-804.","DOI":"10.1007\/s11739-021-02685-0"},{"key":"key-10.14336\/AD.2023.0314-156","doi-asserted-by":"crossref","unstructured":"Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S (2021). Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med, 384:2092-2101.","DOI":"10.1056\/NEJMoa2104840"},{"key":"key-10.14336\/AD.2023.0314-157","doi-asserted-by":"crossref","unstructured":"Garg RK, Paliwal VK (2022). Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci, 43:3-40.","DOI":"10.1007\/s10072-021-05662-9"},{"key":"key-10.14336\/AD.2023.0314-158","doi-asserted-by":"crossref","unstructured":"Driggin E, Maddox TM, Ferdinand KC, Kirkpatrick JN, Ky B, Morris AA et al (2021). ACC Health Policy Statement on Cardiovascular Disease Considerations for COVID-19 Vaccine Prioritization: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol, 77:1938-1948.","DOI":"10.1016\/j.jacc.2021.02.017"},{"key":"key-10.14336\/AD.2023.0314-159","doi-asserted-by":"crossref","unstructured":"Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K et al (2021). A global survey of potential acceptance of a COVID-19 vaccine. Nat Med, 27:225-228.","DOI":"10.1038\/s41591-020-1124-9"},{"key":"key-10.14336\/AD.2023.0314-160","doi-asserted-by":"crossref","unstructured":"Chouchana L, Blet A, Al-Khalaf M, Kafil TS, Nair G, Robblee J et al (2022). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Clin Pharmacol Ther, 111:605-613.","DOI":"10.1002\/cpt.2499"},{"key":"key-10.14336\/AD.2023.0314-161","doi-asserted-by":"crossref","unstructured":"Naghashzadeh F, Shafaghi S, Dorudinia A, Naji SA, Marjani M, Amin A et al (2022). Myocarditis following rAd26 and rAd5 vector-based COVID-19 vaccine: case report. ESC Heart Fail, 9:1483-1486.","DOI":"10.1002\/ehf2.13821"},{"key":"key-10.14336\/AD.2023.0314-162","doi-asserted-by":"crossref","unstructured":"Di Dedda EA, Barison A, Aquaro GD, Ismail TF, Hua A, Mantini C et al (2022). Cardiac magnetic resonance imaging of myocarditis and pericarditis following COVID-19 vaccination: a multicenter collection of 27 cases. Eur Radiol:1-9.","DOI":"10.1007\/s00330-022-08566-0"},{"key":"key-10.14336\/AD.2023.0314-163","doi-asserted-by":"crossref","unstructured":"Kim HW, Jenista ER, Wendell DC, Azevedo CF, Campbell MJ, Darty SN et al (2021). Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol, 6:1196-1201.","DOI":"10.1001\/jamacardio.2021.2828"},{"key":"key-10.14336\/AD.2023.0314-164","doi-asserted-by":"crossref","unstructured":"Perez Y, Levy ER, Joshi AY, Virk A, Rodriguez-Porcel M, Johnson M et al (2021). Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination. Clin Infect Dis. 75:e749-e754","DOI":"10.1093\/cid\/ciab926"},{"key":"key-10.14336\/AD.2023.0314-165","doi-asserted-by":"crossref","unstructured":"Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M et al (2022). Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med, 28:410-422.","DOI":"10.1038\/s41591-021-01630-0"},{"key":"key-10.14336\/AD.2023.0314-166","doi-asserted-by":"crossref","unstructured":"Bozkurt B, Kamat I, Hotez PJ (2021). Myocarditis With COVID-19 mRNA Vaccines. Circulation, 144:471-484.","DOI":"10.1161\/CIRCULATIONAHA.121.056135"},{"key":"key-10.14336\/AD.2023.0314-167","doi-asserted-by":"crossref","unstructured":"Kounis NG, Koniari I, Mplani V, Plotas P, Tsigkas G (2022). First Identified Case of Fatal Fulminant Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Necrotizing Hypersensitivity Reaction Different to Hypersensitivity or Drug-Induced Myocarditis. J Clin Immunol:1-2.","DOI":"10.1007\/s10875-022-01228-2"},{"key":"key-10.14336\/AD.2023.0314-168","doi-asserted-by":"crossref","unstructured":"Pl\u00fc\u00df M, Mese K, Kowallick JT, Schuster A, Tampe D, Tampe B (2021). Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2. Front Immunol, 12:784145.","DOI":"10.3389\/fimmu.2021.784145"},{"key":"key-10.14336\/AD.2023.0314-169","doi-asserted-by":"crossref","unstructured":"Gill JR, Tashjian R, Duncanson E (2022). Autopsy Histopathologic Cardiac Findings in Two Adolescents Following the Second COVID-19 Vaccine Dose. Arch Pathol Lab Med.","DOI":"10.5858\/arpa.2021-0435-SA"},{"key":"key-10.14336\/AD.2023.0314-170","doi-asserted-by":"crossref","unstructured":"Yamaura H, Ishikawa H, Otsuka K, Kasayuki N (2022). Reverse Takotsubo Cardiomyopathy as a Cause of Acute Chest Pain in a Young Woman Following COVID-19 Vaccination. Circ Cardiovasc Imaging, 15:e013661.","DOI":"10.1161\/CIRCIMAGING.121.013661"},{"key":"key-10.14336\/AD.2023.0314-171","doi-asserted-by":"crossref","unstructured":"Garvey LH, Nasser S (2021). Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? Br J Anaesth, 126:e106-e108.","DOI":"10.1016\/j.bja.2020.12.020"},{"key":"key-10.14336\/AD.2023.0314-172","doi-asserted-by":"crossref","unstructured":"Heymans S, Cooper LT (2022). Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms. Nat Rev Cardiol, 19:75-77.","DOI":"10.1038\/s41569-021-00662-w"},{"key":"key-10.14336\/AD.2023.0314-173","doi-asserted-by":"crossref","unstructured":"Maiese A, Frati P, Del Duca F, Santoro P, Manetti AC, La Russa R et al (2021). Myocardial Pathology in COVID-19-Associated Cardiac Injury: A Systematic Review. Diagnostics (Basel), 11.","DOI":"10.3390\/diagnostics11091647"},{"key":"key-10.14336\/AD.2023.0314-174","doi-asserted-by":"crossref","unstructured":"Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y et al (2021). Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med, 385:2132-2139.","DOI":"10.1056\/NEJMoa2110737"},{"key":"key-10.14336\/AD.2023.0314-175","doi-asserted-by":"crossref","unstructured":"Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC (2020). COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol, 17:543-558.","DOI":"10.1038\/s41569-020-0413-9"}],"container-title":["Aging and disease"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T22:06:52Z","timestamp":1705702012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aginganddisease.org\/EN\/10.14336\/AD.2023.0314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":175,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.14336\/ad.2023.0314","relation":{},"ISSN":["2152-5250"],"issn-type":[{"value":"2152-5250","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}